Goldman Sachs Maintains Buy on Alector, Raises Price Target to $33
Goldman Sachs maintains Alector (NASDAQ:ALEC) with a Buy and raises the price target from $29 to $33.
Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients
Alector Inc (NASDAQ: ALEC)
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.
Alector To Present New Data From Frontotemporal Dementia And Alzheimer’s Disease Programs At The 2021 Alzheimer’s Association International Conference
Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN
Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET
SOUTH SAN FRANCISCO, Calif., July 21, 2021 (GLOBE
Understanding Alector’s Unusual Options Activity
Alector (NASDAQ:ALEC) shares experienced unusual options activity on Wednesday. The stock price moved down to $31.15 following the option alert.
Morgan Stanley Maintains Overweight on Alector, Raises Price Target to $57
Morgan Stanley analyst Matthew Harrison maintains Alector (NASDAQ:ALEC) with a Overweight and raises the price target from $33 to $57.
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.
61 Biggest Movers From Yesterday
Gainers
BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday.